Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice

Metabolism: Clinical and Experimental

Volumn 66, Issue , 2017, Pages 32-44

  Bae, Jin Sik ^a   Park, Jong Min ^b   Lee, Junghoon ^a   Oh, Byung Chul ^a   Jang, Sang Ho ^c   Lee, Yun Bin ^b   Han, Young Min ^b   Ock, Chan Young ^b   Cha, Ji Young ^a,d   Hahm, Ki Baik ^b  

^a Gachon University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Bioceltrand Co   (South Korea)

^d Gil University Hospital   (South Korea)

Author keywords

IgY; Liver fibrosis; N 3 PUFAs; NAFLD; NPC1L1

Indexed keywords

CARRIER PROTEIN; EZETIMIBE; IMMUNOGLOBULIN Y; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1; OMEGA 3 FATTY ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ACYL COENZYME A DESATURASE; CAENORHABDITIS ELEGANS PROTEIN; FAT-1 PROTEIN, C ELEGANS; IMMUNOGLOBULIN; NPC1L1 PROTEIN, MOUSE; UNSATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CACO 2 CELL LINE; CELL ACTIVATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; FATTY LIVER; HEPG2 CELL LINE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID DIET; LIVER FIBROSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STELLATE CELL; THERAPY EFFECT; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CACO-2 CELL LINE; DIET THERAPY; GENETICS; HEP-G2 CELL LINE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; CACO-2 CELLS; CAENORHABDITIS ELEGANS PROTEINS; FATTY ACID DESATURASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HEP G2 CELLS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84994482735     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.10.002     Document Type: Article

References (50)

1. [1] Rinella, M.E., Sanyal, A.J., Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 13 (2016), 196–205.
2. [2] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
3. [3] Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65 (2016), 1109–1123.
4. [4] Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004), 147–152.
5. [5] Min, H.K., Kapoor, A., Fuchs, M., Mirshahi, F., Zhou, H., Maher, J., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15 (2012), 665–674.
6. [6] Grundy, S.M., Absorption and metabolism of dietary cholesterol. Annu Rev Nutr 3 (1983), 71–96.
7. [7] Davies, J.P., Levy, B., Ioannou, Y.A., Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 65 (2000), 137–145.
8. [8] Altmann, S.W., Davis, H.R. Jr., Zhu, L.J., Yao, X., Hoos, L.M., Tetzloff, G., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004), 1201–1204.
9. [9] Yu, L., Li-Hawkins, J., Hammer, R.E., Berge, K.E., Horton, J.D., Cohen, J.C., et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110 (2002), 671–680.
10. [10] Chan, D.C., Watts, G.F., Gan, S.K., Ooi, E.M., Barrett, P.H., Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33 (2010), 1134–1139.
11. [11] Jia, L., Betters, J.L., Yu, L., Niemann-Pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 73 (2011), 239–259.
12. [12] Stolk, M.F., Becx, M.C., Kuypers, K.C., Seldenrijk, C.A., Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 4 (2006), 908–911.
13. [13] Florentin, M., Liberopoulos, E.N., Elisaf, M.S., Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 62 (2008), 88–96.
14. [14] Takeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57 (2014), 878–890.
15. [15] Loomba, R., Sirlin, C.B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (Baltimore, Md) 61 (2015), 1239–1250.
16. [16] Scorletti, E., Byrne, C.D., Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 33 (2013), 231–248.
17. [17] Kang, J.X., Wang, J., Wu, L., Kang, Z.B., Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature, 427, 2004, 504.
18. [18] Zhen, Y.H., Jin, L.J., Guo, J., Li, X.Y., Lu, Y.N., Chen, J., et al. Characterization of specific egg yolk immunoglobulin (IgY) against mastitis-causing Escherichia coli. Vet Microbiol 130 (2008), 126–133.
19. [19] Kim, E.H., Bae, J.S., Hahm, K.B., Cha, J.Y., Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease. Biochem Pharmacol 84 (2012), 1359–1365.
20. [20] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(− Delta Delta C(T)) method. Methods 25 (2001), 402–408.
21. [21] Park, S.A., Na, H.K., Kim, E.H., Cha, Y.N., Surh, Y.J., 4-Hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res 69 (2009), 2416–2424.
22. [22] Kang, J.X., Wang, J., A simplified method for analysis of polyunsaturated fatty acids. BMC Biochem, 6, 2005, 5.
23. [23] Li, J., Li, F.R., Wei, D., Jia, W., Kang, J.X., Stefanovic-Racic, M., et al. Endogenous omega-3 polyunsaturated fatty acid production confers resistance to obesity, dyslipidemia, and diabetes in mice. Mol Endocrinol 28 (2014), 1316–1328.
24. [24] Cha, J.Y., Kim, Y.B., Sulfated oxysterol 25HC3S as a therapeutic target of non-alcoholic fatty liver disease. Metabolism 61 (2012), 1055–1057.
25. [25] Repa, J.J., Berge, K.E., Pomajzl, C., Richardson, J.A., Hobbs, H., Mangelsdorf, D.J., Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 277 (2002), 18793–18800.
26. [26] Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., Su, J.L., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272 (1997), 3137–3140.
27. [27] Zhang, Y., Breevoort, S.R., Angdisen, J., Fu, M., Schmidt, D.R., Holmstrom, S.R., et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest 122 (2012), 1688–1699.
28. [28] Shin, D.J., Osborne, T.F., Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner. J Biol Chem 283 (2008), 15089–15096.
29. [29] Oberkofler, H., Schraml, E., Krempler, F., Patsch, W., Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha. Biochem J 371 (2003), 89–96.
30. [30] Halilbasic, E., Claudel, T., Trauner, M., Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 58 (2013), 155–168.
31. [31] Friedman, S.L., Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7 (2010), 425–436.
32. [32] Brown, G.T., Kleiner, D.E., Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65 (2016), 1080–1086.
33. [33] Musso, G., Gambino, R., Cassader, M., Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 52 (2013), 175–191.
34. [34] Trautwein, C., Friedman, S.L., Schuppan, D., Pinzani, M., Hepatic fibrosis: concept to treatment. J Hepatol 62 (2015), S15–S24.
35. [35] Teratani, T., Tomita, K., Suzuki, T., Oshikawa, T., Yokoyama, H., Shimamura, K., et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142 (2012), 152–164, e10.
36. [36] Tomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology (Baltimore, Md) 59 (2014), 154–169.
37. [37] Hernandez-Gea, V., Friedman, S.L., Pathogenesis of liver fibrosis. Annu Rev Pathol 6 (2011), 425–456.
38. [38] Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C.M., Chiang, J.Y., Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology (Baltimore, Md) 52 (2010), 678–690.
39. [39] Li, T., Matozel, M., Boehme, S., Kong, B., Nilsson, L.M., Guo, G., et al. Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology (Baltimore, Md) 53 (2011), 996–1006.
40. [40] Lee, J.M., Lee, Y.K., Mamrosh, J.L., Busby, S.A., Griffin, P.R., Pathak, M.C., et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 474 (2011), 506–510.
41. [41] Su, K., Sabeva, N.S., Liu, J., Wang, Y., Bhatnagar, S., van der Westhuyzen, D.R., et al. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation. J Biol Chem 287 (2012), 28564–28575.
42. [42] Su, K., Sabeva, N.S., Wang, Y., Liu, X., Lester, J.D., Liu, J., et al. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice. Arterioscler Thromb Vasc Biol 34 (2014), 26–33.
43. [43] Zheng, S., Hoos, L., Cook, J., Tetzloff, G., Davis, H. Jr., van Heek, M., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584 (2008), 118–124.
44. [44] Greuter, T., Shah, V.H., Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol 51 (2016), 511–519.
45. [45] Provenzano, A., Milani, S., Vizzutti, F., Delogu, W., Navari, N., Novo, E., et al. N-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. Liver Int 34 (2014), 918–930.
46. [46] Zhang, X., Zhang, Y., Liu, Y., Wang, J., Xu, Q., Yu, X., et al. Medium-chain triglycerides promote macrophage reverse cholesterol transport and improve atherosclerosis in ApoE-deficient mice fed a high-fat diet. Nutr Res 36 (2016), 964–973.
47. [47] Geach, T., Coronary heart disease: NPC1L1 mutations lower CHD risk. Nat Rev Cardiol, 12, 2015, 3.
48. [48] He, J., Shin, H., Wei, X., Kadegowda, A.K., Chen, R., Xie, S.K., NPC1L1 knockout protects against colitis-associated tumorigenesis in mice. BMC Cancer, 15, 2015, 189.
49. [49] Muller, S., Schubert, A., Zajac, J., Dyck, T., Oelkrug, C., IgY antibodies in human nutrition for disease prevention. Nutr J, 14, 2015, 109.
50. [50] Malekshahi, Z.V., Gargari, S.L., Rasooli, I., Ebrahimizadeh, W., Treatment of helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 51 (2011), 366–372.